<DOC>
	<DOCNO>NCT02925104</DOCNO>
	<brief_summary>Dose escalation study ass PK , safety tolerability INC280 take food patient cMET dysregulated advanced solid tumor .</brief_summary>
	<brief_title>A Dose Escalation Study Assess PK , Safety Tolerability INC280 When Taken With Food cMET Dysregulated Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>cMET dysregulated advanced solid tumor At least one measurable lesion define RECIST 1.1 Recovered toxicity relate prior anticancer therapy grade ≤ 1 Adequate organ function ECOG performance status ( PS ) ≤ 1 Prior treatment crizotinib cMET HGF inhibitor Known hypersensitivity excipients INC280 Symptomatic central nervous system ( CNS ) metastases neurologically unstable Presence history malignant disease study relate cancer Clinically significant , uncontrolled heart diseases Thoracic radiotherapy lung field ≤ 4 week prior start INC280 patient recover radiotherapyrelated toxicity Major surgery within 4 week prior start INC280 Impairment GI function Patients receive unstable increase dos corticosteroid Patients receive treatment enzymeinducing anticonvulsant Pregnant nursing ( lactate ) woman Other protocolrelated inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cMET , INC280 , food ,</keyword>
</DOC>